Molecular pathological approach to cancer epigenomics and its clinical application
Author:
Open Access
- 14 March 2024
- journal article
- review article
- Published by Wiley in Pathology International
- Vol. 74 (4) , 167-186
Abstract
Careful microscopic observation of histopathological specimens, accumulation of large numbers of high‐quality tissue specimens, and analysis of molecular pathology in relation to morphological features are considered to yield realistic data on the nature of multistage carcinogenesis. Since the morphological hallmark of cancer is disruption of the normal histological structure maintained through cell−cell adhesiveness and cellular polarity, attempts have been made to investigate abnormalities of the cadherin‐catenin cell adhesion system in human cancer cells. It has been shown that the CDH1 tumor suppressor gene encoding E‐cadherin is silenced by DNA methylation, suggesting that a “double hit” involving DNA methylation and loss of heterozygosity leads to carcinogenesis. Therefore, in the 1990s, we focused on epigenomic mechanisms, which until then had not received much attention. In chronic hepatitis and liver cirrhosis associated with hepatitis virus infection, DNA methylation abnormalities were found to occur frequently, being one of the earliest indications that such abnormalities are present even in precancerous tissue. Aberrant expression and splicing of DNA methyltransferases, such as DNMT1 and DNMT3B, was found to underlie the mechanism of DNA methylation alterations in various organs. The CpG island methylator phenotype in renal cell carcinoma was identified for the first time, and its therapeutic targets were identified by multilayer omics analysis. Furthermore, the DNA methylation profile of nonalcoholic steatohepatitis (NASH)‐related hepatocellular carcinoma was clarified in groundbreaking studies. Since then, we have developed diagnostic markers for carcinogenesis risk in NASH patients and noninvasive diagnostic markers for upper urinary tract cancer, as well as developing a new high‐performance liquid chromatography‐based diagnostic system for DNA methylation diagnosis. Research on the cancer epigenome has revealed that DNA methylation alterations occur from the precancerous stage as a result of exposure to carcinogenic factors such as inflammation, smoking, and viral infections, and continuously contribute to multistage carcinogenesis through aberrant expression of cancer‐related genes and genomic instability. DNA methylation alterations at the precancerous stages are inherited by or strengthened in cancers themselves and determine the clinicopathological aggressiveness of cancers as well as patient outcome. DNA methylation alterations have applications as biomarkers, and are expected to contribute to diagnosis, as well as preventive and preemptive medicine.Keywords
This publication has 117 references indexed in Scilit:
- Relationship between Sphk1/S1P and microRNAs in human cancersBiotechnology and Applied Biochemistry, 2020
- Multilayer‐omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptomeInternational Journal of Cancer, 2014
- Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary diseaseInternational Journal of Cancer, 2013
- Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stageInternational Journal of Cancer, 2011
- Genome‐wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinomaInternational Journal of Cancer, 2009
- Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissuesInternational Journal of Cancer, 2006
- Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomasInternational Journal of Cancer, 2003
- DNA methyltransferase expression and DNA methylation of CPG islands and peri‐centromeric satellite regions in human colorectal and stomach cancersInternational Journal of Cancer, 2001
- Dna Hypermethylation At the D17s5 Locus and Reduced Hic–1 Mrna Expression Are Associated With HepatocarcinogenesisHepatology, 1999
- The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomasInternational Journal of Cancer, 1997